BACKGROUND: The relative 5-year survival rate of @entity5 is moderate at best. This study was set up to evaluate whether the improvements in diagnosis and treatment in the last decades impacted the incidence, mortality and survival of @entity5 . METHODS: Data on @entity1 with @entity5 from 1989 through 2010 were extracted from the Netherlands Cancer Registry (NCR); we examined incidence, mortality and relative survival. Furthermore, information on sex, age, @entity5 stage, histology, and treatment was taken into account. RESULTS: A total of 2737 @entity1 were included. Fifty-three percent (53%) were males and 47% were females with a significant higher proportion of early stages in @entity1 . In 2010, the incidence rate (European Standardized Rate (ESR)) of @entity5 was 0.9 per 100,000 per year. The estimated annual percentage change in incidence rate since 1989 equaled 0.6% (95%CI: -0.2-1.4). Mortality rates (ESR) decreased in @entity1 until 1997 and increased thereafter. Mortality in @entity1 remained stable at 1.5 per 100,000. Over time more @entity1 were treated by surgery and radiotherapy (p<0.001). The relative five-year survival rate equaled 69% and did not change in time. CONCLUSION: We observed no relevant changes in incidence or mortality rates in the last two decades. Despite the increased combined treatment by surgery and radiotherapy, survival did not improve. This implies an urgent need for the development of new effective treatment modalities.

An epidemiological evaluation of XXXX in the Netherlands (1989-2010).

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'salivary gland cancer'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']
@entity5 :: (MESH:D009369,Disease) :: ['salivary gland cancer']
